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Background Atrial fibrillation (AF), whether silent or symptomatic, is a
frequent and severe complication of acute myocardial infarction (AMI).
Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a
risk factor for endothelial dysfunction. We addressed the relationship between
ADMA plasma levels and AF occurrence in AMI.
Methods 273 patients hospitalized for AMI were included. Continuous
electrocardiographic monitoring (CEM) ≥48 hours was recorded and ADMA
was measured by High Performance Liquid Chromatography on admission
blood sample. 
Results The incidence of silent and symptomatic AF was 39(14%) and 29
(11%), respectively. AF patients were markedly older than patients without
AF (≈20y). There was a trend towards higher ADMA levels in patients with
symptomatic AF than in patients with silent AF or no AF (0.53 vs 0.49 and
0.49 μmol/L, respectively). After matching on age, we found that patients with
symptomatic AF had a higher heart rate on admission and a higher rate of
patients with LV dysfunction (28% vs. 3%, p=0.025). Patients who developed
symptomatic AF had a higher ADMA level (0.53 vs. 0.43 μmol/L; p=0.001).
Multivariate logistic regression analysis to estimate symptomatic AF occur-
rence showed that ADMA was independently associated with symptomatic AF
(OR: 2.46 [1.21-5.00], p=0.013) beyond history of AF, LVEF<40% and ele-
vated HR.
Conclusion We show that high ADMA level is associated with the occur-
rence of AF. Although no causative role can be concluded from our observa-
tional study, our work further supports the hypothesis that endothelial
dysfunction is involved in the pathogenesis of AF in AMI. 
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Background CD40 Ligand (CD40L) is expressed on platelets upon ADP
stimulation and is involved in haemostasis. CD40L deficient mice exhibit
thrombus instability and increased bleeding time. 
Methods We investigated the relationships between plasma and platelet-asso-
ciated CD40L, ADP signaling and bleeding event occurrence in patients receiving
thienopyridines one month after a stented Acute Coronary Syndrome (ACS).
Basal platelet CD40L surface expression (pCD40L), pCD40L after PAR-1 agonist
stimulation (TRAP pCD40L) and platelet released CD40L (rCD40L) were quan-
tified. Results were compared to VASP as a measure of P2Y12 inhibition level. 
Results We included 318 patients between November 2012 and June 2014.
Thienopyridines treated patients exhibit low pCD40L, TRAP pCD40L and
rCD40L in comparison with controls. pCD40L and rCD40L were correlated
with PRI-VASP. Thienopyridine treatment strongly reduces rCD40L. Hypere-
sponder to thienopyridine status is associated with high levels of TRAP
pCD40L. pCD40L and TRAP pCD40L levels are reduced in the bleeding
cohort. In multivariate analysis pCD40L significantly contributes to bleeding
risk independently of PRI-VASP.
Conclusion pCD40L and rCD40L levels are reduced by thienopyridines.
pCD40L associates with the bleeding risk independently of the VASP levels
and may represent a novel target to assess bleeding risk in thienopyridine-
treated ACS patients.
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Introduction The Log book (LB) project was created by a multidisci-
plinary team of healthcare professionals from a regional care network and
aimed to improve secondary prevention (SP) after acute myocardial infarction
(MI) in Cote d’Or. LB includes information and advices for increasing self
management of risk factors by the patient. 
Methods A prospective interventional study on 469 patients hospitalised
for an acute MI in the 2 Intensive Coronary Care unit of Côte d’Or (CHU
Dijon and Clinique de Fontaine les Dijon) in 2012 and surviving at 1 year
follow-up (FU). LB was randomly given at the time of their hospitalisation by
the nursing team, also providing oral advices on risk factors management and
CV health self care. Patients who received LB (LB+) were compared with
patients without LB (LB-). 
Results Patients from LB+ group (n=307(65%)) were younger (57 vs 63y,
p<0.001)) and less frequently women (16 vs 32%, p<0.001), diabetic (17 vs
30%, p<0.001) or with prior CAD (7 vs 15%, p=0.008) than patients without
LB (LB- group, n=162(35%)). After matching patients LB+ with LB- based
on age, sex, diabetes and GRACE risk score (n=127 in each group), baseline
characteristics, were similar in the 2 groups. At 1 year FU, there was a trend
for more frequent visits to the cardiologist in the LB+ group (2±1 vs 1±1,
p=0.056) and cardiac rehabilitation program was more often performed in
LB+ patients (69 vs 54%, p=0.015). Moreover, weight loss in obese patients
and smoke withdrawal rates also showed a trend for improvement in LB+
patients (respectively 71 vs 59%, p=0.311 and 69 vs 53%, p=0.109). Finally,
patients with LB showed a trend toward a lower rate of combined outcomes
including recurrent MI, hospitalisation for heart failure and unscheduled PCI
than in the LB- group (3 vs 7%, p=0.155). 
Conclusion These preliminary data of our ongoing regional study suggest
the efficacy of LB as a support for CV risk factor self management. In addi-
tion, our study provides encouraging data on the potential clinical benefits of
this pioneer tool for SP.
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Introduction in animal models of atheroma (ApoE-/- and LDL -/- mice),
bile acids (BAs) exerts an anti-atherosclerotic effect through the anti-inflam-
matory action of their receptors, TGR5 and FXR, decreasing dramatically the
surface of the atheroma plaque. BAs are cholesterol derivatives synthetized by
the liver. In a previous study, we found that a decrease in BAs (lithocholic
acid) is an independent risk factor of coronary disease in human.
